Skip to main content

Market Overview

Synthorx To Be Acquired By Sanofi For $2.5B

Synthorx To Be Acquired By Sanofi For $2.5B

Synthorx, Inc. (NASDAQ: THOR) shares are trading sharply higher after the company announced it would be acquired by Sanofi (NYSE: SNY) for $68 per share in cash, which represents an aggregate equity value of $2.5 billion.

Sanofi expects to complete the acquisition in the first quarter of 2020. The transaction was unanimously approved by both the Sanofi and Synthorx boards of directors.

"This acquisition fits perfectly with our strategy to build a portfolio of high-quality assets and to lead with innovation, as you will hear at our Capital Markets Day tomorrow, December 10. Additionally, it is aligned with our goal to build our oncology franchise with potentially practice-changing medicines and novel combinations," Paul Hudson, CEO of Sanofi said in a statement.

Synthorx shares were trading up 167.68% higher at $67 in Monday's pre-market session. The stock has a 52-week high of $26.78 and a 52-week low of $11.

Related Links:

ArQule To Be Acquired By Merck For $2.7B

Sanofi Trades Higher On Q2 Earnings Beat


Related Articles (THOR + SNY)

View Comments and Join the Discussion!

Posted-In: Biotech M&A News General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at